MMG49 has been identified as a monoclonal antibody that can be targeted using CAR T-cell therapy for patients with multiple myeloma.
Hematologic Cancer Targets
Researchers have discovered that genetic mutations associated with Fanconi Anemia may also result in a higher risk for certain cancers, even in patients who don't exhibit symptoms of the disease.
The FDA has approved inotuzumab ozogamicin (Besponsa) for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia.
The FDA has approved enasidenib (Idhifa) for the treatment of relapsed or refractory IDH2-mutant acute myeloid leukemia.
Researchers at Seattle Children's Research Institute announced the first-in-human clinical trial aimed to extend remission for children and young adults with leukemia treated with CAR T-cell immunotherapy.
On April 28, 2017, the US Food and Drug Administration approved midostaurin (Rydapt) for treating newly diagnosed FLT3-mutated acute myeloid leukemia and three types of systemic mastocytosis.
The FDA has expanded the approval of lenalidomide to include its use as maintenance therapy for patients with multiple myeloma following autologous stem cell transplant.
The FDA has approved daratumumab in combination with lenalidomide and dexamethasone or bortezomib and dexamethasone for patients with multiple myeloma who have received at least one prior therapy.
Genmab recently announced that the US Food and Drug Administration has approved ofatumumab (Arzerra®) combined with fludarabine and cyclophosphamide (FC) for patients with relapsed chronic lymphocytic leukemia.
Treatment with the anti–PD-1 antibody pembrolizumab was safe and active in a small study of patients with relapsed or refractory classical Hodgkin lymphoma whose disease progressed after treatment with brentuximab vedotin.